URGN240719P12500
- 0.05
- 0.000.00%
UroGen Pharma Ltd Newsroom
UroGen Pharma Price Target Maintained With a $60.00/Share by HC Wainwright & Co.
UroGen Pharma Price Target Maintained With a $60.00/Share by HC Wainwright & Co.
HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $60 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $60 price target.
UroGen Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/01/2024 257.57% HC Wainwright & Co. $60 → $60 Reiterates Buy → Buy 06/14/2024 218.83% Ladenburg Thalman
H.C. Wainwright Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $60
H.C. Wainwright analyst Ram Selvaraju maintains $UroGen Pharma Ltd(URGN.US)$ with a buy rating, and maintains the target price at $60.According to TipRanks data, the analyst has a success rate of 36.9
TD Cowen Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Announces Target Price $102
TD Cowen analyst Tara Bancroft maintains $UroGen Pharma Ltd(URGN.US)$ with a buy rating, and sets the target price at $102.According to TipRanks data, the analyst has a success rate of 50.0% and a tot
Goldman Sachs Maintains UroGen Pharma Ltd(URGN.US) With Hold Rating, Maintains Target Price $22
Goldman Sachs analyst Paul Choi maintains $UroGen Pharma Ltd(URGN.US)$ with a hold rating, and maintains the target price at $22.According to TipRanks data, the analyst has a success rate of 0.0% and
UroGen Pharma Stock Slumps After Pricing Stock and Warrants Offering
NextEra Energy, Lennar And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 0.2% on Tuesday.Shares of NextEra Energy, Inc. (NYSE:NEE) fell sharply in today's pre-market trading after the compan
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Ahead of Speeches by Fed Officials
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was marginally down by 0.01% and the actively traded Invesco QQQ Trust (QQQ) was 0.2% higher in Tuesday's premarket activity, as mark
On Monday, UroGen Pharma Priced The Public Offering Of 5M Shares At $17.50/Share, Pre-funded Warrants To Purchase 1.14M Shares At $17.499/Pre-funded Warrant, With Gross Proceeds Of Approximately $107.5M
On Monday, UroGen Pharma Priced The Public Offering Of 5M Shares At $17.50/Share, Pre-funded Warrants To Purchase 1.14M Shares At $17.499/Pre-funded Warrant, With Gross Proceeds Of Approximately $107.
UroGen Pharma Offering Expected to Close June 20 >URGN
UroGen Pharma Offering Expected to Close June 20 >URGN
UroGen Pharma Expects Around $107.5M in Gross Proceeds >URGN
UroGen Pharma Expects Around $107.5M in Gross Proceeds >URGN
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the pricing of an underwritten public
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
PRINCETON, N.J., June 17, 2024 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and
UroGen Pharma Ltd. (NASDAQ:URGN) Held Back By Insufficient Growth Even After Shares Climb 45%
UroGen Pharma Ltd. (NASDAQ:URGN) shares have had a really impressive month, gaining 45% after a shaky period beforehand. Looking back a bit further, it's encouraging to see the stock is up 60% in t
TD Cowen Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating
TD Cowen analyst Tara Bancroft maintains $UroGen Pharma Ltd(URGN.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 53.1% and a total average return of 31.5% over the
Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $40
Oppenheimer analyst Leland Gershell maintains $UroGen Pharma Ltd(URGN.US)$ with a buy rating, and adjusts the target price from $32 to $40.According to TipRanks data, the analyst has a success rate of
UroGen Pharma Is Maintained at Buy by Ladenburg Thalmann
UroGen Pharma Is Maintained at Buy by Ladenburg Thalmann
Ladenburg Thalmann Maintains Buy on UroGen Pharma, Raises Price Target to $53.5
Ladenburg Thalmann analyst Matthew Kaplan maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $48 to $53.5.
UroGen Pharma Shares Are Trading Higher After the Company on Thursday Announced an 82.3% 12-month Duration of Response in Its Phase 3 ENVISION Trial for UGN-102, Achieving a 79.6% Complete Response Rate at Three Months. On Friday, Multiple Analysts...
UroGen Pharma Shares Are Trading Higher After the Company on Thursday Announced an 82.3% 12-month Duration of Response in Its Phase 3 ENVISION Trial for UGN-102, Achieving a 79.6% Complete Response Ra